



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Agrawal, S.	Art Unit:	1635
Serial No.:	09/896,692	Examiner:	TBA
Filing Date:	June 29, 2001		
Title:	<b>Novel HIV-Specific Oligonucleotides and Methods of Their Use</b>		
Attorney Docket Number:	47508.556/HYZ-069CN		

BOX SEQUENCE  
U.S. Patent & Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR § 1.8**

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office with sufficient postage as **First Class Mail** in an envelope addressed to BOX SEQUENCE; U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202 on the date indicated below.

Date: October 15, 2002

  
Patricia J. Byrnes

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES**

Dear Sir:

In response to the above-identified official notice mailed on August 12, 2002, Applicant hereby submits a substitute computer readable form (CRF) copy and one hard copy of the "Sequence Listing." Please substitute the aforementioned (CRF) sequence listing for the one already on file.


The content of the sequence listing information recorded in computer readable form is identical to the written (on paper) sequence listing and includes no new matter as required by 37 CFR §1.821(e), §1.821(f), §1.821(g), §1.825(b), or §1.825(d).

Kindly date stamp the enclosed postcard indicating timely receipt by the Patent Office of the subject documents, and return it to us for our files.

No additional fees are believed due. If however a fee is due or a credit owed, please make it to our Deposit Account No. 08-0219.


Respectfully submitted,

Date: October 15, 2002


  
Ann-Louise Kerner, Ph.D.  
Registration No. 33,523  
Attorney for Applicant


HALE AND DORR LLP  
60 State Street  
Boston, MA 02109  
Tel. (617) 526-6000  
Fax: (617) 526-5000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


 <b>TRANSMITTAL FORM</b> Do not use for all correspondence after initial filing)	Application Number	09/896,692	
	Filing Date	06/29/2001	
	First Named Inventor	Agrawal, S.	
	Group Art Unit	1635	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	6	Attorney Docket Number	47508.556CN2

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Postcard - One Substitute CRF (Diskette) - See Below
Remarks: - One Hard Copy of Substitute CRF (Diskette) - One Copy of and Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Ann-Louise Kerner, Ph.D. (33,523)
Signature	
Date	10/15/2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:			
			10/15/2002
Typed or printed name	Patricia J. Byrnes		
Signature		Date	10/15/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/896,692	06/29/2001	Sudhir Agrawal	47508.556/HYZ-069CN

CONFIRMATION NO. 1859

23483  
HALE AND DORR, LLP  
60 STATE STREET  
BOSTON, MA 02109

## FORMALITIES LETTER



\*OC000000008610073\*

Date Mailed: 08/12/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE